Drug intelligence / Profile preview

fluconazole + terbinafine

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination antifungal therapy that pairs fluconazole (a triazole antifungal) with terbinafine (an allylamine antifungal). This combination provides dual inhibition of fungal ergosterol biosynthesis through different mechanisms, with fluconazole inhibiting lanosterol 14α-demethylase and terbinafine inhibiting squalene epoxidase. The combination has demonstrated synergistic effects against various Candida species, particularly those with reduced susceptibility to azoles, and has shown clinical efficacy in treating resistant fungal infections.

Targets

SQLE (Squalene monooxygenase)CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on fluconazole + terbinafine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluconazole + terbinafine.

Explore the full profile